Коррекция гиперфосфатемии у пациента с терминальной стадией хронической болезни почек и сложным случаем анемии. Клинический случай

Фомин В.В. Коррекция гиперфосфатемии у пациента с терминальной стадией хронической болезни почек и сложным случаем анемии. Клинический случай. Consilium Medicum. 2024;26(1):62–66.
DOI: 10.26442/20751753.2024.1.202777

© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.

________________________________________________

Fomin VV. Correction of hyperphosphatemia in a patient with end-stage chronic kidney disease and a complex case of anemia. A clinical case. Consilium Medicum. 2024;26(1):62–66. DOI: 10.26442/20751753.2024.1.202777

Читать PDF

Аннотация

Препараты железа и/или переливание крови в сочетании с инъекциями рекомбинантного человеческого эритропоэтина регулярно используются для коррекции почечной анемии, которая является частым осложнением терминальной стадии заболевания почек. Однако массивные переливания крови и неадекватное внутривенное введение препаратов железа могут привести к синдрому перегрузки железом, а анемия не всегда носит нефрогенный характер. Представлен редкий клинический случай пациента с терминальной стадией хронической болезни почек со сложным генезом анемии, находящегося на гемодиализе. Случай интересен тем, что назначение препаратов 1-й линии носило угрожающий жизни характер, а для коррекции минерально-костных нарушений препаратом выбора стал севеламер.

Ключевые слова: хроническая болезнь почек, анемия, железо, севеламер, гемодиализ

________________________________________________

Iron supplements and/or blood transfusions in combination with recombinant human erythropoietin injections are routinely used to correct renal anemia, which is a common complication of end-stage renal disease. However, massive blood transfusions and inadequate intravenous iron supplementation can lead to iron overload syndrome, and anemia is not always nephrogenic. A rare clinical case of a patient with end-stage chronic kidney disease with complex genesis of anemia, who is on hemodialysis, is presented. The case is interesting because the prescription of first-line drugs was life-threatening in nature, and sevelamer was the drug chosen for the correction of mineral-bone disorders.

Keywords: chronic kidney disease, anemia, iron, sevelamer, hemodialysis

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006;332(7541):563-4. DOI:10.1136/bmj.332.7541.563
2. Rodriguez M, Felsenfeld AJ. PTH, FGF-23 and early CKD. Nephrol Dial Transplant. 2008;23(11):3391-3. DOI:10.1093/ndt/gfn438
3. Qunibi WY. Cardiovascular calcification in nondialyzed patients with chronic kidney disease. Semin Dial. 2007;20(2):134-8. DOI:10.1111/j.1525-139X.2007.00260.x
4. Coen G, Pierantozzi A, Spizzichino D, et al. Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients. BMC Nephrol. 2010;11(10):1-9. DOI:10.1186/1471-2369-11-10
5. Волгина Г., Селезнев Д., Балкарова О., Ловчинский Е. Внекостная кальцификация у пациентов с хронической болезнью почек. Врач. 2012;(7):2-8 [Volgina G, Seleznev D, Balkarova O, Lovchinsky E. Extraosseous calcification in patients with chronic kidney disease. Vrach. 2012;(7):2-8 (in Russian)].
6. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15(12):2959-64. DOI:10.1097/01.ASN.0000145894.57533.C4
7. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-8. DOI:10.1056/NEJM198701083160203
8. Carter RA, Hawkins JB, Robinson BH. Iron metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron. Br Med J. 1969;3(5664):206-10. DOI:10.1136/bmj.3.5664.206
9. Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol. 1982;17(2):77-81.
10. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141-9. DOI:10.1093/ndt/gfg493
11. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol. 2009;4(1):57-61. DOI:10.2215/CJN.01670408
12. Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6):534-40. DOI:10.1159/000312381
13. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4(8):1384-7. DOI:10.2215/CJN.02190309
14. Zaritsky J, Young B, Wang HJ, et al. Hepcidin – a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051-6. DOI:10.2215/CJN.05931108
15. Волошина Н.Б., Осипенко М.Ф., Литвинова Н.В., Волошин А.Н. Гемохроматоз – современное состояние проблемы. Терапевтический архив. 2018;90(3):107-12 [Voloshinà NB, Osipenko MF, Litvinova NV, Voloshin A.N. Hemochromatosis – modern condition of the problem. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(3):107-12 (in Russian)]. DOI:10.26442/terarkh2018903107-112
16. Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol. 2016;36(2):87-93. DOI:10.1016/j.semnephrol.2016.02.001
17. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis.
2006;47(5 Suppl. 3):S11-145. DOI:10.1053/j.ajkd.2006.03.010. Erratum in: Am J Kidney Dis. 2006;48(3):518.
18. Macginley R, Walker R, Irving M. KHA-CARI Guideline: use of iron in chronic kidney disease patients. Nephrology (Carlton). 2013;18(12):747-9. DOI:10.1111/nep.12139
19. Macdougall IC, Bircher AJ, Eckardt KU, et al; Conference Participants. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;89(1):28-39. DOI:10.1016/j.kint.2015.10.002
20. Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55-62. DOI:10.1159/000085049
21. KDIGO. KDIGO Clinical Practice Guideline for Anemia In Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.
22. Pitts TO, Barbour GL. Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron. 1978;22(4-6):316-21. DOI:10.1159/000181469
23. Brown MC, Gaffney D, Gemmell C, et al. Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis. Hemodial Int. 2009;13(4):460-6. DOI:10.1111/j.1542-4758.2009.00378.x
24. Almasi M, Hajisalimi B. Comparing the effect of sevelamer carbonate versus sevelamer hydrochloride on blood level cholesterol, triglyceride and uric acid in patients undergoing maintenance hemodialysis. J Parathyr Dis. 2020;8:e11173.
25. Covic A, Ketteler M, Rastogi A, et al. Efficacy and Safety of Sucroferric Oxyhydroxide (Velphoro®; Pa21) and Sevelamer Carbonate in Haemodialysis Patients With or Without Diabetes: A Post Hoc Analysis of a Phase 3 Study. Conference: ERA-EDTA. 2014.
26. Nerild HH, Brønden A, Haddouchi AE, et al. Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer. Diabetes Obes Metab. 2024;26(4):1252-63. DOI:10.1111/dom.15421
27. Shakeri H, Panarelli NC. Patterns of gastrointestinal injury in patients with chronic kidney disease: Comparison of cases with and without sevelamer crystals. Histopathology. 2024;84(4):624-32. DOI:10.1111/his.15104

________________________________________________

1. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006;332(7541):563-4. DOI:10.1136/bmj.332.7541.563
2. Rodriguez M, Felsenfeld AJ. PTH, FGF-23 and early CKD. Nephrol Dial Transplant. 2008;23(11):3391-3. DOI:10.1093/ndt/gfn438
3. Qunibi WY. Cardiovascular calcification in nondialyzed patients with chronic kidney disease. Semin Dial. 2007;20(2):134-8. DOI:10.1111/j.1525-139X.2007.00260.x
4. Coen G, Pierantozzi A, Spizzichino D, et al. Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients. BMC Nephrol. 2010;11(10):1-9. DOI:10.1186/1471-2369-11-10
5. Volgina G, Seleznev D, Balkarova O, Lovchinsky E. Extraosseous calcification in patients with chronic kidney disease. Vrach. 2012;(7):2-8 (in Russian).
6. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15(12):2959-64. DOI:10.1097/01.ASN.0000145894.57533.C4
7. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-8. DOI:10.1056/NEJM198701083160203
8. Carter RA, Hawkins JB, Robinson BH. Iron metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron. Br Med J. 1969;3(5664):206-10. DOI:10.1136/bmj.3.5664.206
9. Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol. 1982;17(2):77-81.
10. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141-9. DOI:10.1093/ndt/gfg493
11. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol. 2009;4(1):57-61. DOI:10.2215/CJN.01670408
12. Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6):534-40. DOI:10.1159/000312381
13. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4(8):1384-7. DOI:10.2215/CJN.02190309
14. Zaritsky J, Young B, Wang HJ, et al. Hepcidin – a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051-6. DOI:10.2215/CJN.05931108
15. Voloshinà NB, Osipenko MF, Litvinova NV, Voloshin A.N. Hemochromatosis – modern condition of the problem. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(3):107-12 (in Russian). DOI:10.26442/terarkh2018903107-112
16. Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol. 2016;36(2):87-93. DOI:10.1016/j.semnephrol.2016.02.001
17. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis.
2006;47(5 Suppl. 3):S11-145. DOI:10.1053/j.ajkd.2006.03.010. Erratum in: Am J Kidney Dis. 2006;48(3):518.
18. Macginley R, Walker R, Irving M. KHA-CARI Guideline: use of iron in chronic kidney disease patients. Nephrology (Carlton). 2013;18(12):747-9. DOI:10.1111/nep.12139
19. Macdougall IC, Bircher AJ, Eckardt KU, et al; Conference Participants. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;89(1):28-39. DOI:10.1016/j.kint.2015.10.002
20. Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55-62. DOI:10.1159/000085049
21. KDIGO. KDIGO Clinical Practice Guideline for Anemia In Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.
22. Pitts TO, Barbour GL. Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron. 1978;22(4-6):316-21. DOI:10.1159/000181469
23. Brown MC, Gaffney D, Gemmell C, et al. Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis. Hemodial Int. 2009;13(4):460-6. DOI:10.1111/j.1542-4758.2009.00378.x
24. Almasi M, Hajisalimi B. Comparing the effect of sevelamer carbonate versus sevelamer hydrochloride on blood level cholesterol, triglyceride and uric acid in patients undergoing maintenance hemodialysis. J Parathyr Dis. 2020;8:e11173.
25. Covic A, Ketteler M, Rastogi A, et al. Efficacy and Safety of Sucroferric Oxyhydroxide (Velphoro®; Pa21) and Sevelamer Carbonate in Haemodialysis Patients With or Without Diabetes: A Post Hoc Analysis of a Phase 3 Study. Conference: ERA-EDTA. 2014.
26. Nerild HH, Brønden A, Haddouchi AE, et al. Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer. Diabetes Obes Metab. 2024;26(4):1252-63. DOI:10.1111/dom.15421
27. Shakeri H, Panarelli NC. Patterns of gastrointestinal injury in patients with chronic kidney disease: Comparison of cases with and without sevelamer crystals. Histopathology. 2024;84(4):624-32. DOI:10.1111/his.15104

Авторы

В.В. Фомин*

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*fomin_v_v_1@staff.sechenov.ru

________________________________________________

Victor V. Fomin*

Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*fomin_v_v_1@staff.sechenov.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.